Overview

Fibrosis and the Fontan

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Spironolactone